within Pharmacolibrary.Drugs.ATC.M;

model M01AE57
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.95,
    Cl             = 2.166666666666667e-06,
    adminDuration  = 600,
    adminMass      = 245 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.013,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.003,
    Tlag           = 600
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>M01AE57</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>A fixed-dose combination of naproxen, a nonsteroidal anti-inflammatory drug (NSAID) used for pain and inflammation, and diphenhydramine, a first-generation antihistamine primarily used for allergy symptoms and as a sleep aid. The combination is approved for short-term treatment of occasional sleeplessness associated with minor aches and pains in adults.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters estimated for healthy adult subjects based on individual component data (naproxen 220 mg + diphenhydramine 25 mg orally), as no published clinical pharmacokinetic studies are available for the fixed combination product.</p><h4>References</h4><ol><li><p>Toothaker, RD, et al., &amp; Powell, JH (2000). Absence of pharmacokinetic interaction between orally co-administered naproxen sodium and diphenhydramine hydrochloride. <i>Biopharmaceutics &amp; drug disposition</i> 21(6) 229–233. DOI:<a href=\"https://doi.org/10.1002/bdd.234\">10.1002/bdd.234</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/11304721/\">https://pubmed.ncbi.nlm.nih.gov/11304721</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end M01AE57;
